Venetoclax with hypomethylating agents might lead to eradication of measurable residual disease (MRD) persisting after intensive chemotherapy in acute myeloid leukemia (AML) patients with mutated NPM1 and rearranged CBF

Carlos Jiménez-Vicente; Alexandra Martínez-Roca; Helena Pomares; Sandra Castaño-Diez; Francesca Guijarro; Mònica López-Guerra; Alex Bataller; Daniel Esteban; Albert Cortés-Bullich; Amanda Isabel Pérez-Valencia; Ares Guardia-Torrelles; Inés Zugasti; Montserrat Rovira; Francesc Fernández-Avilés; Dolors Colomer; Montserrat Arnan; Marina Díaz-Beyá; Jordi Esteve

doi:10.1016/j.leukres.2023.107403

Venetoclax with hypomethylating agents might lead to eradication of measurable residual disease (MRD) persisting after intensive chemotherapy in acute myeloid leukemia (AML) patients with mutated NPM1 and rearranged CBF

Leuk Res. 2023 Dec:135:107403. doi: 10.1016/j.leukres.2023.107403. Epub 2023 Sep 30.

Authors

Carlos Jiménez-Vicente¹, Alexandra Martínez-Roca², Helena Pomares³, Sandra Castaño-Diez², Francesca Guijarro⁴, Mònica López-Guerra⁵, Alex Bataller⁶, Daniel Esteban², Albert Cortés-Bullich², Amanda Isabel Pérez-Valencia², Ares Guardia-Torrelles⁷, Inés Zugasti⁷, Montserrat Rovira¹, Francesc Fernández-Avilés², Dolors Colomer⁸, Montserrat Arnan³, Marina Díaz-Beyá⁶, Jordi Esteve⁹

Affiliations

¹ Hematology Department, Hospital Clínic Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; University of Barcelona, Barcelona, Spain.
² Hematology Department, Hospital Clínic Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
³ Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, Barcelona, Spain; Hematology Department, Institut Català d'Oncologia - Hospital Duran i Reynals, Universitat de Barcelona, Barcelona, Spain.
⁴ Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Hemopathology Unit, Pathology Department. Hospital Clinic Barcelona, Spain.
⁵ Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Hemopathology Unit, Pathology Department. Hospital Clinic Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
⁶ Hematology Department, Hospital Clínic Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Josep Carreras Leukemia Research Institute, Barcelona, Spain.
⁷ Hematology Department, Hospital Clínic Barcelona, Spain.
⁸ Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Hemopathology Unit, Pathology Department, Hospital Clínic de Barcelona, Spain.
⁹ Hematology Department, Hospital Clínic Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; University of Barcelona, Barcelona, Spain; Josep Carreras Leukemia Research Institute, Barcelona, Spain. Electronic address: jesteve@clinic.cat.

PMID: 37837718
DOI: 10.1016/j.leukres.2023.107403

No abstract available

Keywords: AML; MRD; Preemptive treatment.

Publication types

Letter

MeSH terms

Bridged Bicyclo Compounds, Heterocyclic / therapeutic use
Humans
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / genetics
Neoplasm, Residual / drug therapy
Nuclear Proteins / genetics
Sulfonamides / therapeutic use

Substances

venetoclax
Nuclear Proteins
Bridged Bicyclo Compounds, Heterocyclic
Sulfonamides